HER2-Positive Breast Cancer: A Guide Through An Evolving Treatment Landscape

Downloadable slides with expert insights on the latest clinical data and expert recommendations to optimize clinical outcomes for your patients with HER2-positive breast cancer.
Jame Abraham, MD, FACP
Hope S. Rugo, MD
Sara Tolaney, MD, MPH

Downloadable Slidesets with ExpressPoints

Download this short summary slideset on current optimal treatment for patients with HER2-positive breast cancer.

Jame Abraham, MD, FACP Hope S. Rugo, MD Sara Tolaney, MD, MPH Released: February 9, 2021

Download these expert-selected slides on optimal treatment of patients with HER2-positive breast cancer with brain metastases.

Sara Tolaney, MD, MPH Released: February 2, 2021

Download these expert-selected slides on optimal testing for HER2 in patients with breast cancer.

Sara Tolaney, MD, MPH Released: February 2, 2021

Download these expert-selected slides on optimal treatment for patients with HER2-positive early breast cancer.

Jame Abraham, MD, FACP Released: February 2, 2021

Download these expert-selected slides on optimal treatment for patients with HER2-positive metastatic breast cancer.

Hope S. Rugo, MD Released: February 3, 2021
Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
NCCN Logo

Karen Kanefield
Manager CE Accreditation & Program Operations
National Comprehensive Cancer Network
3025 Chemical Road, Suite 100
Plymouth Meeting, PA 19462

215-690-0239
215-690-0283 (Fax)
education@nccn.org
For Clinicians:
NCCN.org
For Patients:
NCCN.org/patients

Supported by educational grants from
Genentech, a member of the Roche Group
Puma Biotechnology, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue